Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (71-80 of 209) with videos related to

Pageof 21
Sort By:
Kidney Cancer (Clifton, Va.)|October 19, 2018
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw W Twardowski, Catherine M Tangen, Xiwei Wu, et al.
Cancer|October 17, 2022
Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER dataDaniel D Joyce, Kevin M Wymer, Vidit Sharma, et al.
The Oncologist|June 28, 2017
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 InhibitorsJulia Judd, Matthew Zibelman, Elizabeth Handorf, et al.
The Journal of Urology|November 9, 2019
Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial CarcinomaVitaly Margulis, Maneka Puligandla, Edouard J Trabulsi, et al.
The Journal of Urology|January 23, 2020
Reply by AuthorsVitaly Margulis, Maneka Puligandla, Edouard J Trabulsi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2014
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumorsPaul Haluska, Michael Menefee, Elizabeth R Plimack, et al.
Clinical Genitourinary Cancer|January 25, 2026
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary OncologistsKarine Tawagi, Ali R Khaki, Priyanka V Chablani, et al.
Journal of Oncology Practice|June 23, 2016
Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With CancerCaitlin R Meeker, Daniel M Geynisman, Brian L Egleston, et al.
Urology|July 5, 2011
Clinical Stage T1 micropapillary urothelial carcinoma presenting with metastasis to the pancreasDaniel Canter, Jay Simhan, Marc C Smaldone, et al.
Urology|August 18, 2020
Assessing Contemporary Trends in Female Speakership within Urologic OncologyRuchika Talwar, Adrien Bernstein, Amanda Jones, et al.
Pageof 21

Showing results (71-80 of 209) with videos related to

Sort By:
Pageof 21
Kidney Cancer (Clifton, Va.)|October 19, 2018
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw W Twardowski, Catherine M Tangen, Xiwei Wu, et al.
Cancer|October 17, 2022
Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER dataDaniel D Joyce, Kevin M Wymer, Vidit Sharma, et al.
The Oncologist|June 28, 2017
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 InhibitorsJulia Judd, Matthew Zibelman, Elizabeth Handorf, et al.
The Journal of Urology|November 9, 2019
Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial CarcinomaVitaly Margulis, Maneka Puligandla, Edouard J Trabulsi, et al.
The Journal of Urology|January 23, 2020
Reply by AuthorsVitaly Margulis, Maneka Puligandla, Edouard J Trabulsi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2014
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumorsPaul Haluska, Michael Menefee, Elizabeth R Plimack, et al.
Clinical Genitourinary Cancer|January 25, 2026
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary OncologistsKarine Tawagi, Ali R Khaki, Priyanka V Chablani, et al.
Journal of Oncology Practice|June 23, 2016
Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With CancerCaitlin R Meeker, Daniel M Geynisman, Brian L Egleston, et al.
Urology|July 5, 2011
Clinical Stage T1 micropapillary urothelial carcinoma presenting with metastasis to the pancreasDaniel Canter, Jay Simhan, Marc C Smaldone, et al.
Urology|August 18, 2020
Assessing Contemporary Trends in Female Speakership within Urologic OncologyRuchika Talwar, Adrien Bernstein, Amanda Jones, et al.
Pageof 21